GLUE / Monte Rosa Therapeutics, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of ex

Exhibit 99.1 Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 stu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 MONTE ROSA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commissi

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

As filed with the Securities and Exchange Commission on March 17, 2026

As filed with the Securities and Exchange Commission on March 17, 2026 Registration No.

MONTE ROSA THERAPEUTICS, INC. 2026 INDUCEMENT PLAN

Exhibit 10.4 MONTE ROSA THERAPEUTICS, INC. 2026 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Monte Rosa Therapeutics, Inc. (the “Company”) and its Affiliates to grant equity awards to induce highly-qualified prospecti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 MONTE ROSA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended

Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Monte Rosa Therapeutics, Inc. (the “Company,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fo

MONTE ROSA THERAPEUTICS, INC. 2026 INDUCEMENT PLAN

Exhibit 99.3 MONTE ROSA THERAPEUTICS, INC. 2026 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Monte Rosa Therapeutics, Inc. (the “Company”) and its Affiliates to grant equity awards to induce highly-qualified prospecti

Calculation of Filing Fee Tables Monte Rosa Therapeutics, Inc.

Exhibit 107 Calculation of Filing Fee Tables S-8 Monte Rosa Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Monte Ros

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expa

Exhibit 99.1 Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohort

D. What are the Penalties for Insider Trading and Noncompliance with this Insider Trading Policy? E. How Do You Report a Violation of this Insider Trading Policy? B. Pre-Clearance Procedures C. Exemptions D. Waivers PART III. AMENDMENT PART IV. ACKNO

Exhibit 19.1 MONTE ROSA THERAPEUTICS, INC. AMENDED AND RESTATED Insider Trading POLICY Monte Rosa Therapeutics, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, an

List of Subsidiaries of Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 MONTE ROSA THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

11,125,000 Shares of Common Stock Pre-funded Warrants to Purchase 1,375,000 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285942 Prospectus Supplement (To prospectus dated March 31, 2025) 11,125,000 Shares of Common Stock and Pre-funded Warrants to Purchase 1,375,000 Shares of Common Stock We are offering 11,125,000 shares of our common stock, par value $0.0001 per share, or the common stock, in this offering and, in lieu of common stock to

FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK MONTE ROSA THERAPEUTICS, INC. Number of Shares: [   ] (subject to adjustment) Warrant No. 2026-PF-0[ ] Original Issue Date: January [ ], 2026

EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK MONTE ROSA THERAPEUTICS, INC. Number of Shares: [   ] (subject to adjustment) Warrant No. 2026-PF-0[ ] Original Issue Date: January [ ], 2026 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowle

Monte Rosa Therapeutics, Inc. 11,125,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,375,000 Shares of Common Stock Underwriting Agreement

EX-1.1 Exhibit 1.1 Execution Version Monte Rosa Therapeutics, Inc. 11,125,000 Shares of Common Stock And Pre-Funded Warrants to Purchase 1,375,000 Shares of Common Stock Underwriting Agreement January 8, 2026 Jefferies LLC TD Securities (USA) LLC Piper Sandler & Co. As Representatives of the  several Underwriters listed   in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, New York

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 MONTE ROSA THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering BOSTON, Mass., January 8, 2026 – Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 MONTE ROSA THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 MONTE ROSA THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inclu

Degrading Proteins, Making Medicines MRT-8102 Phase 1 Clinical Data Update January 7, 2026 Exhibit 99.

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degr

Exhibit 99.1 Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in syste

Subject to Completion Preliminary Prospectus Supplement dated January 7, 2026

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285942 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations In mCRPC patients with androge

Exhibit 99.1 Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and

Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inclu

Degrading Proteins, Making Medicines MRT-2359 Phase 1/2 Clinical Data Update December 16, 2025 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 MONTE ROSA THER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 MONTE ROSA THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenan

Exhibit 99.1 Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties Phase 1 study of NEK7-directed MGD MRT-8102 u

COLLABORATION, OPTION AND LICENSE AGREEMENT by and between Novartis Pharma AG Monte Rosa Therapeutics AG September 13, 2025

EXHIBIT 10.1 CONFIDENTIAL Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. COLLABORATION, OPTION AND LICENSE AGREEMENT by and between Novartis Pharma AG and Monte Rosa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 MONTE ROSA THE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (C

About Monte Rosa Forward-Looking Statements

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales Extended cash runway enables Monte Rosa to accelerate preclinical and clinical-stage immunology & inflammation (I&I) pipeline BOSTON, Mass.

LETTER

August 21, 2025 Edmund Dunn SVP, Corporate Controller Monte Rosa Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 MONTE ROSA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammato

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

December 31, 2024

Securities and Exchange Commission July 22, 2025 Page 1 July 22, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.

LETTER

July 15, 2025 Edmund Dunn SVP, Corporate Controller Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, Massachusetts 02118 Re: Monte Rosa Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed March 20, 2025 File No. 001-40522 Dear Edmund Dunn: We have limited our review of your filing to the financial statements and related disclosures and have the follow

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 MONTE ROSA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commissi

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immu

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | May 2025

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | May 2025 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

ARS

UNITEDSTATES SECURITIES ANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ANNUALREPORTPURSUANT TO SECTION13OR 15(d)OFTHESECURITIESEXCHANGEACTOF1934 Forthefiscalyear endedDecember31, 2024 OR TRANSITIONREPORTPURSUANTTO SECTION13OR 15(d) OFTHESECURITIESEXCHANGEACTOF1934FORTHE TRANSITION PERIODFROMTO CommissionFile Number001-40522 MonteRosaTherapeutics, Inc. (Exactnameof Registrantasspecif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118

Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 March 27, 2025 Via EDGAR Transmission Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Monte Rosa Therapeutics, Inc.: Registration Statement on Form S-3 filed March 20, 2025 (File No. 333-285942) Ladies and Gent

LETTER

March 26, 2025 Markus Warmuth, M.D. Chief Executive Officer Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 Re: Monte Rosa Therapeutics, Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285942 Dear Markus Warmuth M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.6 MONTE ROSA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monte Rosa Therapeutics, Inc.

List of Subsidiaries of the Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts

Form of Senior Indenture between Registrant and one or more trustees to be named

Exhibit 4.5 MONTE ROSA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Cert

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | March 2025

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | March 2025 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

License Agreement between Monte Rosa Therapeutics AG and Novartis Pharma AG, dated as of October 25, 2024

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.

Monte Rosa Therapeutics, Inc. Amended and Restated Compensation Recovery Policy

Monte Rosa Therapeutics, Inc. COMPENSATION RECOVERY POLICY Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 MONTE ROSA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

Power of Attorney (included on the signature pages to the Registration Statement)

S-3 Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther

Insider Trading Policy and Rule 10b5-1 Trading Plan Policy

MONTE ROSA THERAPEUTICS, INC. AMENDED AND RESTATED Insider Trading POLICY Monte Rosa Therapeutics, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation o

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following

Amendment No. 1. to Open Market Sale AgreementSM, dated March 20, 2025, between the Registrant and Jefferies LLC

Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM March 20, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (the “Amendment No. 1”) is entered into as of the date first written above by and between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC, as s

Filing Fee Table.

Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Monte Rosa Therapeutics, Inc.

As filed with the Securities and Exchange Commission on March 20, 2025

As filed with the Securities and Exchange Commission on March 20, 2025 Registration No.

EX-24

EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam

EX-99

EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 Aperio Group, LLC BlackRock Advisors, LLC SpiderRock Advisors, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outsta

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 31, 2025 with respect to the Common Stock, $0.0001 par value per share, of Monte Rosa Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accord

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 MONTE ROSA THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025

Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Ph

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Year-end cash and equivalents expected to be $377 million as of December 31, 2024 (unaudited) and anticipated to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Company to present at J.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 MONTE ROSA THER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | December 2024

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | December 2024 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and ta

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 MONTE ROSA THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

GLUE / Monte Rosa Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 glue13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) MONTE ROSA THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 61225M102 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the

GLUE / Monte Rosa Therapeutics, Inc. / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 MONTE ROSA THERAPEUTICS INC COMMON STOCK Cusip #61225M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61225M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,100,211 Item 6: 0 Item 7: 5,101,413 Item 8: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders includi

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M upfront payment, eligible for up to $2.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

GLUE / Monte Rosa Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d886758dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Secur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 MONTE ROSA THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportun

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.

GLUE / Monte Rosa Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number

GLUE / Monte Rosa Therapeutics, Inc. / New Enterprise Associates 17, L.P. - NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#2) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 61225M102 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093

GLUE / Monte Rosa Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phas

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical data expected in Q1 2025 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrated a favorable safety and pharmacodynamic profile at 0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

Amended and Restated Employment Agreement between the Registrant and Jennifer Champoux, effective as of May 28, 2024 (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40522) filed on August 8, 2024)

Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Jennifer Champoux (the “Executive”) and is effective as of May 28, 2024 (the “Effective Date”). WHEREAS, the Company and the Executive are parties to prior Employment Agreements tha

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; curr

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

Monte Rosa Therapeutics Announces Leadership Team Promotions

EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Leadership Team Promotions BOSTON, Mass., May 30, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 MONTE ROSA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss

Underwriting Agreement, dated May 15, 2024, by and between Monte Rosa Therapeutics, Inc. and TD Securities (USA) LLC, as representative of the several underwriters listed on Schedule 1 thereto.

Exhibit 1.1 Monte Rosa Therapeutics, Inc. 10,638,476 Shares of Common Stock And Pre-Funded Warrants to Purchase 10,638,524 Shares of Common Stock Underwriting Agreement May 15, 2024 TD Securities (USA) LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Monte Rosa Therapeutics,

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Exhibit 99.1 Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering BOSTON, Mass., May 16, 2024 – Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at

10,638,476 Shares of Common Stock Pre-funded Warrants to Purchase 10,638,524 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266003 Prospectus Supplement (To prospectus dated July 13, 2022) 10,638,476 Shares of Common Stock and Pre-funded Warrants to Purchase 10,638,524 Shares of Common Stock We are offering 10,638,476 shares of our common stock, par value $0.0001 per share, or the common stock, in this offering and, in lieu of common stock to certa

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss

Form of Pre-Funded Warrant.

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK MONTE ROSA THERAPEUTICS, INC. Number of Shares: [   ] (subject to adjustment) Warrant No. 2024-PF-0[ ] Original Issue Date: May [ ], 2024 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [    

Subject to Completion Preliminary Prospectus Supplement dated May 15, 2024

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266003 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these

GLUE / Monte Rosa Therapeutics, Inc. / New Enterprise Associates 17, L.P. - NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#1) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 61225M102 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093

Second Amended and Restated By-laws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.3 of the Registrant's Quarterly Report on Form 10-Q (File No. 001-40522) filed on May 9, 2024)

Exhibit 3.3 SECOND AMENDED AND RESTATED BYLAWS OF MONTE ROSA THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or in the manner determined by the Board of

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination o

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024; Phase 1 clinical data anticipated in H2 2024 MRT-6160, a VAV1-directed MGD in development for systemic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | May 2024

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | May 2024 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commissi

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Boa

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board BOSTON, Mass., May 2, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue d

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

ARS

UNITEDSTATES SECURITIES AND EXCHANGECOMMISSION Washington,D.C.20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OFTHE SECURITIESEXCHANGEACT OF 1934 Forthe fiscalyear endedDecember31, 2023 OR ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OFTHE SECURITIES EXCHANGEACT OF 1934 FORTHE TRANSITION PERIODFROMTO Commission File Number 001-40522 MonteRosaTherapeutics, Inc. (

GLUE / Monte Rosa Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) MONTE ROSA THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 61225M102 (CUSIP NUMBER) March 31, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sche

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2024

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2024 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther

Description of Securities (incorporated by reference to Exhibit 4.2 of the Registrant’s Annual Report on Form 10-K (File No. 001-40522) filed with the Securities and Exchange Commission on March 24, 2024).

Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Monte Rosa Therapeutics, Inc. (the “Company,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fo

List of Subsidiaries of the Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts

Monte Rosa Therapeutics, Inc. Compensation Recovery Policy

Exhibit 97.1 Monte Rosa Therapeutics, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 27, 2023 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Co

As filed with the Securities and Exchange Commission on March 14, 2024

As filed with the Securities and Exchange Commission on March 14, 2024 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

Filing Fee Table.

Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial;

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 MRT-6160, a VAV1-directed MGD designed to treat systemic and neuro

GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP - AMENDMENT NO. 3 Passive Investment

SC 13G/A 1 sc13ga.htm AMENDMENT NO. 3 CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check

GLUE / Monte Rosa Therapeutics, Inc. / BlackRock Inc. Passive Investment

us61225m1027021424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) MONTE ROSA THERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 61225M102 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

GLUE / Monte Rosa Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

GLUE / Monte Rosa Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) MONTE ROSA THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 61225M102 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S

GLUE / Monte Rosa Therapeutics, Inc. / Avoro Capital Advisors LLC - MONTE ROSA THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-0276sc13ga.htm MONTE ROSA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of Thi

GLUE / Monte Rosa Therapeutics, Inc. / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.3 MONTE ROSA THERAPEUTICS INC COMMON STOCK Cusip #61225M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61225M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,536,696 Item 6: 0 Item 7: 5,537,239 Item 8: 0 Item 9: 5,537,239 Ite

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MONTE ROSA THERAP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2024

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2024 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designa

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously treated, metastatic small cell lung cancer with L- or N-MYC expression MRT-6160, a VAV1-directed MGD, anticipated to initiate Phase 1 study in mid-2024, supporting potential future Phase 2 proof-of-concept studies in multiple autoimmune diseases Strong cash position expected to fund operations into H1 2026 and enable advancement of pipeline programs through significant early clinical milestones Company to present at J.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Collaboration and License Agreement between Monte Rosa Therapeutics AG, F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., dated as of October 16, 2023 (incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q filed on November 9, 2023)

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.

GLUE / Monte Rosa Therapeutics Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d494819dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Secur

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel molecular glue degraders targeting cancer and neurological di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 MONTE ROSA THERA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

Securities Purchase Agreement, dated October 26, 2023 (incorporated by reference to Exhibit 10.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on October 26, 2023)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 26, 2023, by and among Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Investors wish to purchase from the Compa

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on October 26, 2023)

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK MONTE ROSA THERAPEUTICS, INC. Number of Shares: [    ] (subject to adjustment)     Warrant No. 2023-PF-0[ ] Original Issue Date: October [ ], 2023 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledg

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

Exhibit 99.1 Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules BOSTON, Mass., October 26, 2023 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised $25 million at-the-market from a life sciences-dedicat

Pre-funded warrants to purchase 10,000,400 Shares of Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266003 Prospectus Supplement (To prospectus dated July 13, 2022) Pre-funded warrants to purchase 10,000,400 Shares of Common Stock We are offering pre-funded warrants to purchase 10,000,400 shares of our common stock, in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine with Roche’s strong expertise in delivering transformative therapies to patients Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion BOSTON, Mass.

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent wi

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a.

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Separation Agreement between the Registrant and Ajim Tamboli, effective as of August 8, 2023.

Exhibit 10.1 August 9, 2023 PERSONAL AND CONFIDENTIAL Ajim Tamboli, CFA Re: Separation Agreement Dear Ajim: This letter will confirm your resignation from Monte Rosa Therapeutics, Inc. (the “Company”) effective August 8, 2023 (the “Separation Date”). This letter also sets forth the terms of a separation agreement between you and the Company (the “Agreement”) that would provide you with severance p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update ● On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023 ● Received Orphan Drug Designation from the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 MONTE ROSA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MONTE ROSA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-40522) filed on June 14, 2023)

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Monte Rosa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was ori

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update • On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023 • Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection points BOSTON, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MONTE ROSA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

ARS

UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934 ForthefiscalyearendedDecember31,2022 OR ☐ TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934FORTHE TRANSITIONPERIODFROM TO CommissionFileNumber001-40522 MonteRosaTherapeutics,Inc. (ExactnameofRegistrantasspecifiedinits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MONTE ROSA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on March 16, 2023

As filed with the Securities and Exchange Commission on March 16, 2023 Registration No.

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2023

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Filing Fee Table.

Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update • Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing • Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 • MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression • Nomination of multiple development candidates anticipated in 2023 • Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 – Monte Rosa Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther

List of Subsidiaries of the Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 MONTE ROSA THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

GLUE / Monte Rosa Therapeutics, Inc. / Avoro Capital Advisors LLC - MONTE ROSA THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p23-0270sc13ga.htm MONTE ROSA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of Thi

GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment

SC 13G/A 1 sc13g.htm CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b

GLUE / Monte Rosa Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 glue13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) MONTE ROSA THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 61225M102 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the

GLUE / Monte Rosa Therapeutics, Inc. / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 MONTE ROSA THERAPEUTICS INC COMMON STOCK Cusip #61225M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61225M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,217,159 Item 6: 0 Item 7: 6,217,458 Item 8: 0

GLUE / Monte Rosa Therapeutics, Inc. / BlackRock Inc. Passive Investment

us61225m1027020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) MONTE ROSA THERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 61225M102 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

EX-99.2 3 glue-ex992.htm EX-99.2 Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 • MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression • Disclosure of initial data from Phase 1 arm of ong

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2023

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates – Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors – – Pro

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates ? Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors ? ? Progressed VAV1 Molecular Glue Degrader Program into Lead Optimization ? BOSTON, November 10, 2022 ? Monte Rosa Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include a

Exhibit 99.1 MRT-2359 KOL Webinar hosted by Cowen October 24, 2022 Guest Speakers Jordi Rodon Ahnert, M.D., Ph.D., Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center Davide Ruggero, Ph.D., Professor, Department of Urology and Cellular & Molecular Pharmacology at UCSF; Helen Diller Family Endowed Chair in Basic Cancer Research Forward-Looking

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates – Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – –

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates ? Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors ? ? Cash Runway into Late 2024 with $299.

July 11, 2022

July 11, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

LETTER

United States securities and exchange commission logo July 8, 2022 Markus Warmuth, M.

Form of Senior Indenture between Registrant and one or more trustees to be named

Exhibit 4.5 MONTE ROSA THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s

As filed with the Securities and Exchange Commission on July 1, 2022

Table of Contents As filed with the Securities and Exchange Commission on July 1, 2022 Registration No.

Form of Subordinated Indenture between Registrant and one or more trustees to be named

Exhibit 4.6 MONTE ROSA THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monte Rosa Therapeutics, Inc.

Open Market Sale AgreementSM, dated as of July 1, 2022, between the Registrant and Jefferies LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM July 1, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s comm

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates – Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader i

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates ? Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year ? ? Initiated Research with ?cole Polytechnique F?d?rale de Lausanne (EPFL); Collaboration to Broaden Monte Rosa?s AI Capabilities ? BOSTON, May 11, 2022 ? Monte Rosa Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Agreement for Termination of Lease, by and between the Registrant and OPG MP Parcel Owner (DE) LLC, dated May 5, 2022 (incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q filed on May 11, 2022)

Exhibit 10.2 AGREEMENT FOR TERMINATION OF LEASE This AGREEMENT FOR TERMINATION OF LEASE (this ?Agreement?) is entered into as of this 5th day of May, 2022 (the ?Effective Date?), by and between OPG MP PARCEL OWNER (DE) LLC, a Delaware limited liability company (?Landlord?), and MONTE ROSA THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Recitals A. Landlord is the owner of certain real prope

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates – Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Mol

Exhibit 99.1 Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates ? Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 ? ? Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into Lead Optimization ? ? Year-end Cash and Cash Equivalents Expected to Provide Runway into Late 2024 ? B

Filing Fee Table.

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Monte Rosa Therapeutics, Inc.

Lease Agreement between the Registrant and B9 LS Harrison & Washington LLC, dated December 14, 2021 (incorporated by reference by reference to Exhibit 10.20 of the Registrant's Annual Report on Form 10-K filed March 29. 2022)

Exhibit 10.20 LEASE by and between B9 LS HARRISON & WASHINGTON LLC, a Delaware limited liability company and MONTE ROSA THERAPEUTICS, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 5 4. Possession and Commencement Date. 6 5. Condition of Premises 8 6. Rentable Area 8 7. Rent 9 8. Rent Adjustments 10 9. Operating Expenses 10 10. Taxes on Te

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi

Amended and Restated Employment Agreement between the Registrant and Philip Nickson, effective as of March 1, 2022 (incorporated by reference to Exhibit 10.22 of the Registrant's Annual Report on Form 10-K filed March 29, 2022)

Exhibit 10.22 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Philip Nickson, JD, Ph.D. (the ?Executive?) and is effective as of March 1, 2022 (the ?Effective Date?). WHEREAS, the Company and the Executive are parties to an Employment Agreement that

Employment Agreement between the Registrant and Jullian Jones, effective as of June 28, 2021, as amended by the First Amendment to Employment Agreement, effective as of December 1, 2021 (incorporated by reference by reference to Exhibit 10.21 of the Registrant's Annual Report on Form 10-K filed March 29. 2022)

Exhibit 10.21 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Jullian Jones, Ph.D., J.D., MBA (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securitie

As filed with the Securities and Exchange Commission on March 29, 2022

As filed with the Securities and Exchange Commission on March 29, 2022 Registration No.

List of Subsidiaries of the Registrant

Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts

Description of Securities (incorporated by reference to Exhibit 4.2 of the Registrant’s Annual Report on Form 10-K (File No. 001-40522) filed with the Securities and Exchange Commission on March 29, 2022).

Exhibit 4.2 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Monte Rosa Therapeutics, Inc. (the ?Company,? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther

GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment

CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r

GLUE / Monte Rosa Therapeutics, Inc. / Avoro Capital Advisors LLC - MONTE ROSA THERAPEUTICS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu

GLUE / Monte Rosa Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Monte Rosa Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 61225M102 (CUSIP NUMBER) January 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this

GLUE / Monte Rosa Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Monte Rosa Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 61225M102 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this

GLUE / Monte Rosa Therapeutics, Inc. / FMR LLC Passive Investment

SCHEDULE 13G Amendment No. 1 MONTE ROSA THERAPEUTICS INC COMMON STOCK Cusip #61225M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61225M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,323,298 Item 6: 0 Item 7: 6,975,887 Item 8: 0 Item 9: 6,975,887 It

GLUE / Monte Rosa Therapeutics, Inc. / BlackRock Inc. Passive Investment

us61225m1027020922.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) MONTE ROSA THERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 61225M102 - (CUSIP Number) January 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

GLUE / Monte Rosa Therapeutics, Inc. / BlackRock Inc. Passive Investment

us61225m1027020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) MONTE ROSA THERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 61225M102 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com

These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not

From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2022 Exhibit 99.

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates – Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Tar

Exhibit 99.1 Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates ? Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 ? ? Presented Preclinical Data at AACR-NCI-EORTC Highlighting the Potential of GSPT1-directed Molecular Glue Degraders for t

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress – Completed upsized $255.6 million IPO; cash runway extended into late 2024 – Continued advancement of QuEENTM protein degradation pla

Exhibit 99.1 Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress ? Completed upsized $255.6 million IPO; cash runway extended into late 2024 ? Continued advancement of QuEENTM protein degradation platform and pipeline of molecular glue degraders, including NEK7 program ? BOSTON, August 12, 2021 ? Monte Rosa Therapeutics, Inc. (NASDAQ:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm

GLUE / Monte Rosa Therapeutics, Inc. / FMR LLC Passive Investment

SCHEDULE 13G Amendment No. 0 MONTE ROSA THERAPEUTICS INC COMMON STOCK Cusip #61225M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #61225M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,309,095 Item 6: 0 Item 7: 6,172,277 Item 8: 0 Item 9: 6,172,277 It

GLUE / Monte Rosa Therapeutics, Inc. / New Enterprise Associates 17, L.P. - NEW ENTERPRISE ASSOCIATES 17, L.P. / MONTE ROSA THERAPEUTICS, INC. -- SCHEDULE 13D Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 6122JM102 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 2

FORM OF LOCK-UP AGREEMENT

Exhibit 3 FORM OF LOCK-UP AGREEMENT June 19, 2021 J.P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, NY 1022 c/o Piper Sandler

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 8, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihua Ch

Joint Filing Agreement

Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Monte Rosa Therapeutics, Inc.

GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment

CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) June 28, 2021† (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

GLUE / Monte Rosa Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) V

Fourth Amended and Restated Certificate of Incorporation of Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K (File No. 001-40522) filed on June 28, 2021).

Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. Monte Rosa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Monte Rosa Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis

Amended and Restated By-laws (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40522) filed with the Securities and Exchange Commission on June 28, 2021).

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF MONTE ROSA THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla

Form S-8

As filed with the Securities and Exchange Commission on June 25, 2021 Registration No.

2021 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 99.2 of the Registrant’s Registration Statement on Form S-8 (File No. 333-257406) filed on June 25, 2021)

Exhibit 99.2 MONTE ROSA THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Monte Rosa Therapeutics, Inc. (the ?Compa

Overview of protein degradation

424B4 1 d47776d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-256773 Prospectus 11,700,000 Shares Common stock This is an initial public offering of shares of common stock by Monte Rosa Therapeutics, Inc. We are offering 11,700,000 shares of common stock. The initial public offering price is $19.00 per share. Prior to this offering, there has been

As filed with the Securities and Exchange Commission on June 23, 2021.

As filed with the Securities and Exchange Commission on June 23, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 81-3766197 (State or other jurisdiction of (Primary Standard Industrial

REDACTED EXHIBIT

June 23, 2021 Ajim Tamboli Chief Financial Officer Monte Rosa Therapeutics, Inc. 645 Summer Street, Suite 102 Boston, MA 02210 Re: Monte Rosa Therapeutics, Inc. Registration Statement on Form S-1 Exhibit Nos. 10.14, 10.15, 10.16, 10.17 Filed June 4, 2021 File No. 333-256773 Dear Mr. Tamboli: We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements

CERT

The Nasdaq Stock Market LLC, 805 King Farm Blvd., Rockville, MD 20850 Arnold Golub Vice President, Deputy General Counsel Office of General Counsel June 22, 2021 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporate Finance: This is to certify that on June 21, 2021, The Nasdaq Stock Market (the "Exchange") received f

Form S-1, as amended (File No. 333-256773)

Table of Contents As filed with the Securities and Exchange Commission on June 21, 2021 Registration No.

Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-256773))

Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Monte Rosa THERAPEUTICS Certificate Number ZQ00000000 MONTE ROSA THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT is the owner of MR. SAMPLE & MRS. SAMPLE & MR. SAMPLE & MRS. SAMPLE ***ZERO HUNDRED THOUSAND ZERO HUNDRED AND ZERO*** Shares * * 000000

2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the registrant’s Registration Statement on Form S-1, as amended (File No. 333-256773)).

Exhibit 10.2 MONTE ROSA THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Monte Rosa Therapeutics, Inc. (the ?Compa

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-3766197 (State of incorporation or organization) (I.R.S. Employer Identification No.) 645 Summer Str

[Remainder of page left intentionally blank]

CORRESP 1 filename1.htm VIA EDGAR June 21, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attn: Kasey Robinson Jeffrey Gabor Re: Monte Rosa Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-256773 Requested Date: June 23, 2021 Requested Time: 4:00 p.m. Eastern Standard T

Employment Agreement between the Registrant and Markus Warmuth, effective as of June 28, 2021 (incorporated by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-256773)

Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Markus Warmuth, M.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 193

Employment Agreement between the Registrant and Ajim Tamboli, effective as of June 28, 2021 (incorporated by reference to Exhibit 10.8 of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-256773))

Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Ajim Tamboli, CFA (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933,